VK2809 found that those on the medicine saw statistically significant reductions in liver fat, meeting the primary endpoint.
Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Hosted on MSN1y
Viking Therapeutics stock climbs as liver drug shows efficacy among key patient subgroupsViking Therapeutics (NASDAQ:VKTX) shares gained over 5% in extended trading on Monday after the drugmaker reported positive findings from an ongoing study of its lead drug candidate, VK2809.
The company plans to escalate VK2735 dosages and start Phase 2 trials, with Phase 3 trials for the injectable version and VK2809 NASH drug also in the pipeline. The stock has a market cap below $9 ...
With no approved/marketed product in its portfolio, the company is focused on developing three drugs in its portfolio — VK2735 (for obesity), VK2809 (for non-alcoholic steatohepatitis [NASH ...
End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH ...
VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback